Physician profile
Marc E Hofmann
NPI 1861498313
$49,106.75
in general payments reported to CMS, 2019-2025
48 companies · $1,418 in 2025
The $1,418 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23K · 2020: $3,108 · 2021: $5,666 · 2022: $2,422 · 2023: $11K · 2024: $2,224 · 2025: $1,418.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,075 · Food and Beverage: $6,039 · Travel and Lodging: $598 · Education: $141.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,075.00 |
| Food and Beverage | $6,038.90 |
| Travel and Lodging | $598.21 |
| Education | $140.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $30,654.46 | 2019-2025 | Xywav |
| Axsome Therapeutics, INC. | $9,458.79 | 2023-2025 | Sunosi |
| Glaxosmithkline, LLC. | $2,219.66 | 2020-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Harmony Biosciences LLC | $1,672.46 | 2020-2025 | Wakix |
| Astrazeneca Pharmaceuticals Lp | $909.95 | 2020-2025 | Airsupra, Breztri, Fasenra |
| Avadel Cns Pharmaceuticals, LLC | $413.92 | 2023-2025 | Lumryz |
| Actelion Pharmaceuticals US, INC. | $412.77 | 2021-2025 | Opsumit, Uptravi |
| United Therapeutics Corporation | $278.36 | 2021-2025 | Tyvaso, Orenitram |
| Fisher & Paykel Healthcare INC | $260.33 | 2022-2025 | Fisher & Paykel Healthcare |
| Ucb, INC. | $221.15 | 2019 | |
| Lilly USA, LLC | $181.29 | 2019-2025 | Zepbound, Mounjaro |
| Philips North America LLC | $175.36 | 2019-2025 | Patient Interface Software, Encore |
| Idorsia Pharmaceuticals US INC | $147.45 | 2022-2023 | Quviviq |
| Verona Pharma, INC. | $138.77 | 2025 | Ohtuvayre |
| Eisai INC. | $138.76 | 2019-2022 |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $137.59 | 2019-2020 | |
| Baxter Healthcare | $118.86 | 2022-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Monarch Airway Clearance System, Hillrom - Synclara Cough System |
| Arbor Pharmaceuticals, INC. | $118.41 | 2019-2021 | |
| Grifols USA, LLC | $105.73 | 2019-2025 | Prolastin-C Liquid |
| Insmed, INC. | $102.45 | 2025 | Arikayce, Brinsupri |
| Tanabe Pharma America, INC. | $100.47 | 2019-2020 | |
| Genzyme Corporation | $100.12 | 2019-2024 | |
| Lundbeck LLC | $98.60 | 2019-2020 | |
| Csl Behring | $96.75 | 2019-2020 | |
| Resmed Corp | $89.03 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $81.90 | 2019 | |
| Biogen, INC. | $74.02 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.56 | 2025 | Ofev, Jascayd |
| Inogen, INC. | $51.18 | 2022-2023 | Inogen At Home Stationary Concentrator, Inogen One G5 Oxygen Concentrator - Bluetooth |
| Electromed, INC. | $47.09 | 2024 | Smartvest |
| Mylan Specialty L.P. | $42.99 | 2022-2024 | Yupelri |
| Vanda Pharmaceuticals INC. | $41.98 | 2019-2021 | |
| Boston Scientific Corporation | $39.74 | 2022-2023 | |
| Teva Pharmaceuticals USA, INC. | $34.74 | 2020-2021 | |
| 3b Medical, INC. | $32.54 | 2023-2025 | Luna |
| Abbott Laboratories | $31.09 | 2020 | |
| Advanced Respiratory, INC | $29.30 | 2021 | |
| Zoll Respicardia, INC. | $24.63 | 2022 | |
| Abbvie INC. | $24.44 | 2021 | |
| Azurity Pharmaceuticals, INC. | $23.35 | 2023 | Horizant |
| Akcea Therapeutics, INC. | $18.98 | 2019 | |
| Inspire Medical Systems, INC. | $18.17 | 2025 | Inspire |
| Vapotherm INC | $17.76 | 2022 | |
| Alnylam Pharmaceuticals INC. | $15.22 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.82 | 2021 | |
| Neurocrine Biosciences, INC. | $14.55 | 2020 | |
| Snap Diagnostics LLC | $13.92 | 2024 | Snap Diagnostics Study |
| Amneal Pharmaceuticals LLC | $11.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Hofmann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.